Market Cap: $2.37B
SI
Supernus Pharmaceuticals, Inc.
SUPN
NASDAQ (NASDAQ Global Market)USD
Market Cap: $2.37B
Supernus Pharmaceuticals (SUPN) has recently unveiled a strategic partnership with MERGE, marking a significant development in its marketing and digital ecosystem management. This collaboration comes…
Supernus Pharmaceuticals: A Strong Performance Drives Future Growth Outlook Supernus Pharmaceuticals announces its Q4 earnings results for 2026, showcasing impressive financial performance that reinfo…
Supernus Pharmaceuticals Achieves Strong Q4 Earnings and Signals Ambitious Growth Plans Supernus Pharmaceuticals, a company renowned for its innovative treatments in the neurological space, announces…
Supernus Pharmaceuticals: A Rising Star in the Pharmaceutical Sector Supernus Pharmaceuticals is gaining recognition for its potential growth as it attracts attention from analysts, particularly Bank…
Supernus Pharmaceuticals Advances Treatment Options for Neurological Disorders Supernus Pharmaceuticals, a key player in the development of innovative therapies for central nervous system (CNS) disord…
Supernus Pharmaceuticals Prepares for Key Earnings Announcement Amidst Growing Investor Interest Supernus Pharmaceuticals is poised to announce its quarterly earnings on November 4, 2025, an event tha…
Supernus Pharmaceuticals Secures Positive Analyst Attention Amid Market Dynamics In a noteworthy development this week, Supernus Pharmaceuticals garners a "buy" rating from Bank of America, accompanie…
Supernus Pharmaceuticals Navigates Diverse Analyst Opinions Amid Evolving Market Conditions Supernus Pharmaceuticals, a prominent player in the pharmaceutical industry, finds itself at a crossroads as…
Pharmaceutical Tariffs Shift Industry Dynamics The recent announcement by President Donald Trump regarding a 100% tariff on imported branded and patented medicines has sent shockwaves through the U.S.…
Executives Signal Confidence Amid Strategic Developments at Supernus Pharmaceuticals Frank Mottola, Senior Vice President at Supernus Pharmaceuticals, recently exercises a substantial number of stock…
Supernus Pharmaceuticals: Executive Confidence in Innovative Therapeutics Frank Mottola, Senior Vice President at Supernus Pharmaceuticals, demonstrates a notable act of confidence in the company's fu…
Supernus Pharmaceuticals Insider Activity Signals Strategic Confidence Recent insider activity at Supernus Pharmaceuticals garners attention as Senior Vice President Mottola exercises a significant se…
Supernus Pharmaceuticals Faces Scrutiny Following Insider Sale Supernus Pharmaceuticals, a company dedicated to developing treatments for central nervous system diseases, draws significant attention f…
Supernus Pharmaceuticals Expands Reach with Strategic Acquisition of Sage Therapeutics Supernus Pharmaceuticals, Inc. announces a significant strategic acquisition of Sage Therapeutics, Inc. for appro…
Supernus Pharmaceuticals Expands CNS Portfolio with Sage Therapeutics Acquisition In a strategic move to enhance its position in the pharmaceutical industry, Supernus Pharmaceuticals, Inc. announces i…
Supernus Pharmaceuticals Expands CNS Portfolio with Sage Therapeutics Acquisition Supernus Pharmaceuticals, Inc. announces a strategic acquisition of Sage Therapeutics, Inc., agreeing to purchase the…
Newron Pharmaceuticals Partners with EA Pharma to Advance Schizophrenia Treatment Newron Pharmaceuticals S.p.A. has forged a pivotal licensing agreement with EA Pharma Co., Ltd., a subsidiary of Eisai…
Strategic Focus on Innovative Biotech Solutions at Supernus Pharmaceuticals Supernus Pharmaceuticals positions itself as a key player in the biotechnology landscape, emphasizing the development of inn…